{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:04:26Z","timestamp":1778695466427,"version":"3.51.4"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The Omicron variant is phylogenetically and antigenically distinct from earlier SARS-CoV-2 variants and the original vaccine strain. Protection conferred by prior SARS-CoV-2 infection against Omicron reinfection, with and without vaccination, requires quantification.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the protection against Omicron reinfection and hospitalization conferred by prior heterologous non-Omicron SARS-CoV-2 infection and\/or up to 3 doses of an ancestral, Wuhan-like messenger RNA (mRNA) vaccine.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This test-negative, population-based case-control study was conducted between December 26, 2021, and March 12, 2022, and included community-dwelling individuals aged 12 years or older who were tested for SARS-CoV-2 infection in the province of Quebec, Canada.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Prior laboratory-confirmed SARS-CoV-2 infection with or without mRNA vaccination.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome was laboratory-confirmed SARS-CoV-2 reinfection and associated hospitalization, presumed to be associated with the Omicron variant according to genomic surveillance. The odds of prior infection with or without vaccination were compared for case participants with Omicron infection and associated hospitalizations vs test-negative control participants. Estimated protection was derived as 1 \u2212 the odds ratio, adjusted for age, sex, testing indication, and epidemiologic week. Analyses were stratified by severity and time since last non-Omicron infection or vaccine dose.<\/jats:p><\/jats:sec>Results<\/jats:title>This study included 696 439 individuals (224 007 case participants and 472 432 control participants); 62.2% and 63.9% were female and 87.4% and 75.5% were aged 18 to 69 years, respectively. Prior non-Omicron SARS-CoV-2 infection was detected for 9505 case participants (4.2%) and 29\u202f712 control participants (6.3%). Among nonvaccinated individuals, prior non-Omicron infection was associated with a 44% reduction (95% CI, 38%-48%) in Omicron reinfection risk, which decreased from 66% (95% CI, 57%-73%) at 3 to 5 months to 35% (95% CI, 21%-47%) at 9 to 11 months postinfection and was below 30% thereafter. The more severe the prior infection, the greater the risk reduction. Estimated protection (95% CI) against Omicron infection was consistently significantly higher among vaccinated individuals with prior infection compared with vaccinated infection-naive individuals, with 65% (63%-67%) vs 20% (16%-24%) for 1 dose, 68% (67%-70%) vs 42% (41%-44%) for 2 doses, and 83% (81%-84%) vs 73% (72%-73%) for 3 doses. For individuals with prior infection, estimated protection (95% CI) against Omicron-associated hospitalization was 81% (66%-89%) and increased to 86% (77%-99%) with 1, 94% (91%-96%) with 2, and 97% (94%-99%) with 3 mRNA vaccine doses, without signs of waning.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this study suggest that vaccination with 2 or 3 mRNA vaccine doses among individuals with prior heterologous SARS-CoV-2 infection provided the greatest protection against Omicron-associated hospitalization. In the context of program goals to prevent severe outcomes and preserve health care system capacity, a third mRNA vaccine dose may add limited protection in twice-vaccinated individuals with prior SARS-CoV-2 infection.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.36670","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T15:34:48Z","timestamp":1665761688000},"page":"e2236670","source":"Crossref","is-referenced-by-count":47,"title":["Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA\u2013Vaccinated and Nonvaccinated Individuals in Quebec, Canada"],"prefix":"10.1001","volume":"5","author":[{"given":"Sara","family":"Carazo","sequence":"first","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta M.","family":"Skowronski","sequence":"additional","affiliation":[{"name":"Communicable Diseases and Immunization Services, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Brisson","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"},{"name":"Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"},{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"},{"name":"Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Brousseau","sequence":"additional","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"},{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"},{"name":"Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"Gilca","sequence":"additional","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"},{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"},{"name":"Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manale","family":"Ouakki","sequence":"additional","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapha","family":"Barkati","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Center, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Fafard","sequence":"additional","affiliation":[{"name":"Laboratoire de Sant\u00e9 Publique du Qu\u00e9bec, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Sainte-Anne-de-Bellevue, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Talbot","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"},{"name":"Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Gilca","sequence":"additional","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Deceuninck","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Garenc","sequence":"additional","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"},{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Carignan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Sherbrook University, Sherbrook, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"De Wals","sequence":"additional","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"},{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"},{"name":"Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"De Serres","sequence":"additional","affiliation":[{"name":"Biological Risks Unit, Institut National de Sant\u00e9 Publique du Qu\u00e9bec, Quebec City, Quebec, Canada"},{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Quebec City, Quebec, Canada"},{"name":"Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"6593","key":"zoi221041r1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.","volume":"376","author":"Pulliam","year":"2022","journal-title":"Science"},{"issue":"4","key":"zoi221041r2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.4.2101196","article-title":"Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022.","volume":"27","author":"Eggink","year":"2022","journal-title":"Euro Surveill"},{"key":"zoi221041r3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.884121","article-title":"Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study.","volume":"10","author":"Flacco","year":"2022","journal-title":"Front Public Health"},{"issue":"16","key":"zoi221041r4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi221041r6","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.10.2003121","article-title":"Updated rapid risk assessment from ECDC on the novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU\/EEA and the UK.","volume":"25","author":"Eurosurveillance Editorial Team","year":"2020","journal-title":"Euro Surveill"},{"issue":"3","key":"zoi221041r8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmi.2020.11.028","article-title":"Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity.","volume":"27","author":"Yahav","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"zoi221041r11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac290","article-title":"Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada.","author":"Skowronski","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"27","key":"zoi221041r12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi221041r13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine.","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi221041r16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection.","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi221041r17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1473-3099(21)00676-9","article-title":"Protective immunity after recovery from SARS-CoV-2 infection.","volume":"22","author":"Kojima","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"zoi221041r18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(22)00143-8","article-title":"Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.","volume":"22","author":"Nordstr\u00f6m","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"zoi221041r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2022.112911","article-title":"SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity.","volume":"209","author":"Pilz","year":"2022","journal-title":"Environ Res"},{"issue":"4","key":"zoi221041r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7650","article-title":"Rates of COVID-19 among unvaccinated adults with prior COVID-19.","volume":"5","author":"Ridgway","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"13","key":"zoi221041r21","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJMc2200133","article-title":"Protection against the Omicron variant from previous SARS-CoV-2 infection.","volume":"386","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi221041r22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac161","article-title":"Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.","author":"\u0160m\u00edd","year":"2022","journal-title":"J Infect Dis"},{"key":"zoi221041r23","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4054807","article-title":"Observed protection against SARS-CoV-2 reinfection following a primary infection: a Danish cohort study using two years of nationwide PCR-test data.","author":"Michlmayr","year":"2022","journal-title":"SSRN"},{"issue":"44","key":"zoi221041r24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.15585\/mmwr.mm7044e1","article-title":"Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity\u2014nine states, January-September 2021.","volume":"70","author":"Bozio","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi221041r25","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1093\/cid\/ciac262","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity, reinfections versus breakthrough infections: a retrospective cohort study.","volume":"75","author":"Gazit","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"23","key":"zoi221041r26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2.","volume":"386","author":"Goldberg","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi221041r27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijid.2022.02.015","article-title":"Incidence of SARS-CoV-2 infection among previously infected or vaccinated employees.","volume":"118","author":"Kojima","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"2","key":"zoi221041r28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.2021.9970","article-title":"Associations of vaccination and of prior infection with positive PCR test results for SARS-CoV-2 in airline passengers arriving in Qatar.","volume":"326","author":"Bertollini","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"zoi221041r29","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1038\/s41467-022-29858-5","article-title":"Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel.","volume":"13","author":"Waxman","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"zoi221041r32","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1038\/s41467-022-31838-8","article-title":"Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.","volume":"13","author":"Andeweg","year":"2022","journal-title":"Nat Commun"},{"issue":"12","key":"zoi221041r33","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.cmi.2021.07.024","article-title":"Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.","volume":"27","author":"Buonfrate","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"10279","key":"zoi221041r34","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.","volume":"397","author":"Manisty","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"zoi221041r35","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2666-5247(21)00275-5","article-title":"T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.","volume":"3","author":"Angyal","year":"2022","journal-title":"Lancet Microbe"},{"issue":"4","key":"zoi221041r36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19.","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"issue":"5","key":"zoi221041r37","doi-asserted-by":"publisher","first-page":"674","DOI":"10.7326\/M21-4130","article-title":"The incidence of SARS-CoV-2 reinfection in persons with naturally acquired immunity with and without subsequent receipt of a single dose of BNT162b2 vaccine: a retrospective cohort study.","volume":"175","author":"Gazit","year":"2022","journal-title":"Ann Intern Med"},{"issue":"13","key":"zoi221041r38","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa2119497","article-title":"Effectiveness of the BNT162b2 vaccine after recovery from Covid-19.","volume":"386","author":"Hammerman","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi221041r39","doi-asserted-by":"publisher","first-page":"e662","DOI":"10.1093\/cid\/ciac022","article-title":"Necessity of coronavirus disease 2019 (COVID-19) vaccination in persons who have already had COVID-19.","volume":"75","author":"Shrestha","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"15","key":"zoi221041r40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.15585\/mmwr.mm7115e2","article-title":"Effectiveness of COVID-19 mRNA vaccination in preventing COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection\u2014United States, June 2021-February 2022.","volume":"71","author":"Plumb","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi221041r41","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/ije\/dym021","article-title":"Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness.","volume":"36","author":"Orenstein","year":"2007","journal-title":"Int J Epidemiol"},{"issue":"15","key":"zoi221041r42","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMe2113151","article-title":"Covid-19 vaccine effectiveness and the test-negative design.","volume":"385","author":"Dean","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi221041r43","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1016\/S2214-109X(21)00593-3","article-title":"Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.","volume":"10","author":"Parker","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"1","key":"zoi221041r44","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1186\/s12879-021-06643-1","article-title":"Symptomatic SARS-COV-2 reinfection: healthcare workers and immunosuppressed individuals at high risk.","volume":"21","author":"Murillo-Zamora","year":"2021","journal-title":"BMC Infect Dis"},{"key":"zoi221041r5","unstructured":"Worldometer. COVID-19 coronavirus pandemic. April 1, 2022. Accessed April 1, 2022. https:\/\/www.worldometers.info\/coronavirus\/"},{"key":"zoi221041r7","unstructured":"Minist\u00e8re de la Sant\u00e9 et des Services Sociaux du Qu\u00e9bec. Toutes les directives COVID-19 d\u00e9pistage. Gouvernement du Qu\u00e9bec. 2022. Accessed April 1, 2022. https:\/\/publications.msss.gouv.qc.ca\/msss\/directives-covid-19\/sujets\/depistage"},{"key":"zoi221041r9","unstructured":"Institut National de Sant\u00e9 Publique du Qu\u00e9bec. Donn\u00e9es sur les variants du SRAS-CoV-2 au Qu\u00e9bec. April 1, 2022. Accessed April 1, 2022. https:\/\/www.inspq.qc.ca\/covid-19\/donnees\/variants"},{"key":"zoi221041r10","unstructured":"Institut National de Sant\u00e9 Publique du Qu\u00e9bec. Donn\u00e9es de vaccination contre la COVID-19 au Qu\u00e9bec. April 1, 2022. Accessed April 1, 2022. https:\/\/www.inspq.qc.ca\/covid-19\/donnees\/vaccination"},{"key":"zoi221041r14","unstructured":"Comit\u00e9 sur l\u2019Immunization du Qu\u00e9bec. Avis portant sur la pertinence d\u2019une dose additionnelle de vaccin contre la COVID-19 pour les personnes ayant une immunod\u00e9pression. August 30, 2021. Accessed March 24, 2022. https:\/\/www.inspq.qc.ca\/publications\/3163-pertinence-dose-additionnelle-vaccin-covid-19-immunodeprimes"},{"key":"zoi221041r15","unstructured":"Comit\u00e9 sur l\u2019immunization du Qu\u00e9bec. Pertinence d\u2019une dose de rappel d\u2019un vaccin contre la COVID-19 Pour les diff\u00e9rentes cat\u00e9gories d\u2019adultes au Qu\u00e9bec. Institut National de Sant\u00e9 Publique du Qu\u00e9bec. 2021. Accessed March 15, 2022. https:\/\/www.inspq.qc.ca\/sites\/default\/files\/publications\/3184-pertinence-rappel-vaccin-covid-19-adultes.pdf"},{"key":"zoi221041r30","doi-asserted-by":"crossref","unstructured":"Chemaitelly? H, Ayoub? HH, AlMukdad? S, . Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar.? medRxiv. Preprint posted online March 18, 2022. doi:10.1101\/2022.03.17.22272529?","DOI":"10.1101\/2022.03.17.22272529"},{"key":"zoi221041r31","doi-asserted-by":"crossref","unstructured":"Altarawneh? HN, Chemaitelly? H, Ayoub? H, . Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar.? medRxiv. Preprint posted online March 18, 2022. doi:10.1101\/2022.03.22.22272745?","DOI":"10.1101\/2022.03.22.22272745"},{"key":"zoi221041r45","doi-asserted-by":"crossref","unstructured":"Stegger? M, Edslev? SM, Sieber? RN, . Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection.? medRxiv. Preprint posted online February 22, 2022. doi:10.1101\/2022.02.19.22271112?","DOI":"10.1101\/2022.02.19.22271112"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797311\/carazo_2022_oi_221041_1664988079.5059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T15:34:59Z","timestamp":1665761699000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36670","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}